SCHEMBL3629773

SCHEMBL3629773

CC(C)(C)c1cc(O)[nH]n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.44
TSHR P16473 1/20 0.44
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
CYP1A2 P05177 1/20 0.33
MAPT P10636 1/20 0.33
ALOX15 P16050 1/20 0.33
ATP2A2 P16615 1/20 0.33
ATP2A3 Q93084 1/20 0.33
LMNA P02545 1/20 0.33
PTGS1 P23219 3/20 0.33
PTGS2 P35354 2/20 0.33
ALOX5 P09917 1/20 0.33
GABRA1 P14867 1/20 0.32
GABRB2 P47870 1/20 0.32
HCAR2 Q8TDS4 2/20 0.31
CA2 P00918 2/20 0.31
CA1 P00915 1/20 0.31
GRN P28799 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1461090 0.76 MAPK1 (0.34) HPGDALOX15LMNACA2POLB
Hydrochloric Acid SCHEMBL4028288 0.74 MAPK1 (0.37) HPGDSMN1; SMN2ALOX15LMNACA2
SCHEMBL15821070 0.74 HPGD (0.43) HPGDTSHRKDM4EALDH1A1SMN1; SMN2
SCHEMBL1205789 0.73 HPGD (0.46) HPGDTSHRKDM4ESMN1; SMN2LMNA
SCHEMBL179497 0.73 HPGD (0.50) HPGDTSHRKDM4ESMN1; SMN2MAPT
SCHEMBL16423877 0.73 HPGD (0.55) HPGDTSHRKDM4EALDH1A1MAPT
SCHEMBL16920575 0.71 HPGD (0.44) HPGDTSHRSMN1; SMN2LMNA
SCHEMBL21719751 0.71 HPGD (0.44) HPGDTSHRLMNA
SCHEMBL21720026 0.71 HPGD (0.44) HPGDTSHRLMNA
SCHEMBL179529 0.71 HPGD (0.44) HPGDTSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230193231-A1 ENGINEERED GENE-EDITING PROTEINS FACTOR BIOSCIENCE INC. 2023-06-22 US disclosed
US-20230111853-A1 COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION ORIONIS BIOSCIENCES, INC. 2023-04-13 US disclosed
US-20220169611-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer AMGEN INC (US) 2022-06-02 US disclosed
US-20220122691-A1 HtrA Inhibitors and CagA Inhibitors and Use Thereof Psomagen Inc. (US) 2022-04-21 US disclosed
US-20220048893-A1 Compounds for Treating Neurodegenerative Diseases and Cancers HONGYI & ASS LLC (US) 2022-02-17 US disclosed
US-20210179560-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer AMGEN INC (US) 2021-06-17 US disclosed
US-20210009505-A1 CATIONIC LIPIDS AND TRANSFECTION METHODS FACTOR BIOSCIENCE INC. 2021-01-14 US disclosed
US-10550106-B2 Compounds, compositions, and methods for modulating CFTR PROTEOSTASIS THERAPEUTICS, INC. (US) 2020-02-04 US disclosed
US-9682938-B2 Pyrazolone derivatives as nitroxyl donors CARDIOXYL PHARMACEUTICALS, INC. (US) 2017-06-20 US disclosed
US-20170144971-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer AMGEN INC. (US) 2017-05-25 US disclosed
US-7704310-B2 Trisazo-dyes with a pyrazolyl end group and their use in ink-jet printing FUJIFILM IMAGING COLORANTS LIMITED (GB) 2010-04-27 US disclosed
WO-2010018874-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 WO disclosed
US-20100041891-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 US disclosed
US-20100015411-A1 Trisazo-dyes with a Pyrazolyl End Group and Their Use in Ink-jet Printing FUJIFILM IMAGING COLORANTS LIMITED (GB) 2010-01-21 US disclosed
US-20100015411-A1 Trisazo-dyes with a Pyrazolyl End Group and Their Use in Ink-jet Printing FUJIFILM IMAGING COLORANTS LIMITED (GB) 2010-01-21 US disclosed
US-20080269220-A1 Aminophenylpropanoic Acid Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-30 US disclosed
WO-2008047071-A1 TRISAZO-DYES WITH A PYRAZOLYL END GROUP AND THEIR USE IN INK-JET PRINTING FUJIFILM IMAGING COLORANTS LIMITED (GB) 2008-04-24 WO disclosed
EP-1726580-A1 AMINOPHENYLPROPANOIC ACID DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2006-11-29 EP disclosed
US-4163052-A NEMATOCIDES, FUNGICIDES, ARTHROPODICIDES BAYER AKTIENGESELLSCHAFT (DE) 1979-07-31 US disclosed
US-4146632-A NEMATOCIDES, ARTHROPODICIDES BAYER AKTIENGESELLSCHAFT (DE) 1979-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230111853-A1 COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION CRBN, STUB1, ADRM1 HPGD 4375/4885TSHR 3805/4885KDM4E 971/4885
US-20100041891-A1 AMIDE COMPOUND GPR52, GPR132, NR5A2 HPGD 2979/4885TSHR 240/4885KDM4E 3467/4885
US-20220169611-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer MDM2, TP53, CDKN1A HPGD 347/4885TSHR 4432/4885KDM4E 734/4885
US-20210179560-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer MDM2, TP53, CDKN1A HPGD 347/4885TSHR 4432/4885KDM4E 734/4885
US-20080269220-A1 Aminophenylpropanoic Acid Derivative GPR119, GPR55, GPR65 HPGD 2123/4885TSHR 1762/4885KDM4E 1965/4885
US-10550106-B2 Compounds, compositions, and methods for modulating CFTR CFTR, SCNN1B, SCNN1G HPGD 2072/4885TSHR 3900/4885KDM4E 4558/4885
US-20220048893-A1 Compounds for Treating Neurodegenerative Diseases and Cancers SNCA, NGF, SLC18A2 HPGD 1682/4885TSHR 3595/4885KDM4E 1151/4885
US-20220122691-A1 HtrA Inhibitors and CagA Inhibitors and Use Thereof HTRA1, GIPR, HPN HPGD 1284/4885TSHR 1902/4885KDM4E 4426/4885
US-20170144971-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer MDM2, TP53, CDKN1A HPGD 347/4885TSHR 4432/4885KDM4E 734/4885
US-20210009505-A1 CATIONIC LIPIDS AND TRANSFECTION METHODS CETP, NPC1L1, NPC1 HPGD 4601/4885TSHR 1775/4885KDM4E 4264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.